Adagene (ADAG)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from ADAG's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Adagene's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $10M | $9M | $18M | $103,204 | $8M |
| Net income | -$73M | -$80M | -$19M | -$33M | -$18M |
| Free cash flow | -$46M | -$49M | -$29M | -$30M | -$16M |
| EPS (diluted) | -$1.46 | -$0.31 | -$0.35 | -$0.59 | -$0.30 |
| Operating margin | -711.2% | -903.1% | -131.0% | -34835.4% | -279.5% |
Superinvestors who own ADAG
From each investor's latest 13F filing (what a 13F shows).
Insider buying
Open-market purchases by Adagene's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Sep 23, 2026 | Man Kin Tam Chief Financial Officer |
2,000 | $3.00 | $6,000 |
| Sep 16, 2026 | Peter Luo Chief Executive Officer |
20,290 | $3.15 | $63,980 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when ADAG trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Adagene insiders buying the stock?
2 open-market insider purchases of ADAG in the last 12 months, from SEC Form 4 filings.
Companies like Adagene
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.